Viking Therapeutics (VKTX) Set to Announce Quarterly Earnings on Wednesday

Viking Therapeutics (NASDAQ:VKTX) is scheduled to be announcing its earnings results after the market closes on Wednesday, October 23rd. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings data on Wednesday, July 24th. The biotechnology company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.06. During the same quarter in the prior year, the company earned ($0.19) EPS. On average, analysts expect Viking Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Viking Therapeutics Price Performance

Shares of VKTX stock opened at $65.80 on Monday. The company has a market capitalization of $7.26 billion, a price-to-earnings ratio of -70.75 and a beta of 1.00. Viking Therapeutics has a one year low of $8.28 and a one year high of $99.41. The company’s fifty day moving average price is $62.64 and its 200-day moving average price is $61.95.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on VKTX shares. Morgan Stanley restated an “overweight” rating and set a $105.00 price objective on shares of Viking Therapeutics in a research report on Thursday, September 12th. HC Wainwright reaffirmed a “buy” rating and set a $90.00 target price on shares of Viking Therapeutics in a research note on Wednesday, October 9th. JPMorgan Chase & Co. started coverage on shares of Viking Therapeutics in a research note on Wednesday, September 11th. They set an “overweight” rating and a $80.00 target price for the company. Raymond James raised their target price on shares of Viking Therapeutics from $116.00 to $118.00 and gave the company a “strong-buy” rating in a research note on Thursday, July 25th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $138.00 target price on shares of Viking Therapeutics in a research note on Wednesday, September 25th. One equities research analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Viking Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $108.60.

Insiders Place Their Bets

In other Viking Therapeutics news, CEO Brian Lian sold 115,859 shares of Viking Therapeutics stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $57.58, for a total value of $6,671,161.22. Following the completion of the transaction, the chief executive officer now directly owns 2,354,927 shares of the company’s stock, valued at $135,596,696.66. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In other Viking Therapeutics news, CEO Brian Lian sold 115,859 shares of Viking Therapeutics stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $57.58, for a total value of $6,671,161.22. Following the completion of the transaction, the chief executive officer now directly owns 2,354,927 shares of the company’s stock, valued at $135,596,696.66. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director J Matthew Singleton sold 10,300 shares of the firm’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $69.50, for a total transaction of $715,850.00. Following the completion of the sale, the director now owns 9,500 shares of the company’s stock, valued at $660,250. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 516,671 shares of company stock valued at $33,810,813 in the last three months. Corporate insiders own 4.70% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.